A groundbreaking study from Japan has revealed that molecules commonly found in trendy anti-aging treatments may inadvertently feed cancer cells, raising significant health concerns. Polyamines, natural compounds present in all living cells, are celebrated for triggering autophagy—the body's essential cellular cleanup process where damaged components are broken down and reused.
The Double-Edged Sword of Cellular Cleanup
By recycling damaged cell parts, autophagy plays a crucial role in destroying pathogens and eliminating cellular debris that can slow overall bodily performance. As aging progresses, autophagy naturally decreases, leading to an accumulation of cellular 'junk.' To counteract this decline, many anti-aging skincare products and dietary supplements incorporate polyamines, particularly specific subsets known as spermidine and putrescine.
Previous research has linked these polyamines to extended lifespans and reductions in age-related memory decline, making them popular ingredients in wellness regimens. However, the 2025 study conducted by experts at the Tokyo University of Science presents a starkly different narrative, suggesting that spermidine and other polyamines may heighten the risk of cancer metastasis.
Laboratory Findings on Cancer Progression
In their meticulous investigation, researchers took lab cultures of cervical and breast cancer cells and deliberately depleted them of polyamines. After manually restoring the polyamines using spermidine, they analyzed over 6,700 proteins and uncovered a troubling mechanism. Polyamines were found to activate glycolysis, a process that rapidly converts glucose into energy, thereby driving cancer progression instead of supporting healthy aging pathways.
Furthermore, polyamines increase the expression of certain proteins, including the protein EIF5A2, which has been strongly associated with cancer spread. The team discovered that EIF5A2 stimulation is typically suppressed by an RNA molecule called miR-6514-5p. However, polyamines interfere with this natural suppression, allowing EIF5A2 levels to rise and promoting unchecked cancer cell growth.
Implications for Cancer Statistics and Treatment
The researchers noted in their study, published in the Journal of Biological Chemistry, that 'Changes in polyamine metabolism are correlated with various pathologies, including cancer and age-related conditions.' These findings emerge against a backdrop of alarming cancer statistics. According to the American Cancer Society, approximately 324,000 women are expected to be diagnosed with breast cancer this year, with around 42,000 fatalities. Meanwhile, an estimated 13,000 will be diagnosed with cervical cancer in the US in 2026, resulting in about 4,200 deaths.
Prior to this study, scientists were aware of two forms of the protein ELF5A: ELF5A1, widely expressed in normal tissues, and EIF5A2, which is overexpressed in cancers. However, the reason behind their divergent roles remained unclear. To investigate, the team used human cancer cell cultures, known as HeLa S3 cells, and depleted them of polyamines using drugs that inhibit synthesis. They then restored polyamines by adding spermidine.
Mechanisms of Polyamine Action in Cancer
The research revealed that polyamines activate both ELF5A1 and EIF5A2, but with vastly different outcomes. In ELF5A1, polyamines target the cell's mitochondria and trigger beneficial autophagy. In contrast, in EIF5A2, polyamines inhibit miR-6514-5p, leading to accelerated cancer cell spread and a shift in gene expression toward pathways conducive to cancer growth.
Additionally, polyamines increased the expression of ribosomal proteins, such as RPS27A, RPL36A, and RPL22L1, all of which are linked to tumor aggressiveness and metastasis. Kyohei Higashi, study author and biochemist at the Tokyo University of Science, emphasized, 'The biological activity of polyamines via EIF5A differs between normal and cancer tissues.'
Clarifying the Cancer Connection
The researchers caution that their study does not prove polyamines in general cause cancer. Instead, the results demonstrate that once cancer has initiated, malignant cells can hijack polyamines to enhance their survival and proliferation. This nuanced understanding highlights the complex interplay between aging interventions and cancer risks.
The team also noted that comprehending the roles of EIF5A and miR-6514-5p could pave the way for innovative cancer treatments. They wrote, 'Our findings reveal an important role for eIF5A2, regulated by polyamines and miR-6514-5p, in cancer cell proliferation, suggesting that the interaction between eIF5A2 and ribosomes, which regulate cancer progression, is a selective target for cancer treatment.'
This research underscores the need for further investigation into how polyamines impact genes related to cancer progression, particularly in breast and cervical cancers, where the exact mechanisms remain partially unclear. As anti-aging products continue to gain popularity, these findings serve as a critical reminder of the potential unintended consequences lurking within seemingly beneficial compounds.
